Valsartan plus hydrochlorothiazide versus valsartan alone in uncontrolled mild to moderate hypertension

Phase 3, randomised, double-blind trial of valsartan and hydrochlorothiazide in hypertension (HTN) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough mean sitting diastolic blood pressure at endpoint. Started Aug 2004; status: completed.